COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy

ConditionCovid19
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAventyn, Inc.

About this trial

Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital technology using wearables and mobile app tools. Researchers aim to study in Phase 1, epidemiological variations in COVID-19 presentation in both PCR positive and negative subjects in the registry. Assessment of variables, predictive modeling of variables that impact severity of COVID-19 positive and negative subjects and assessment of predictors for post COVID-19 complications. In Phase 2, 2700 subjects with COVID-19 positive test will be studied in the intervention group comparing ECL-19 vs placebo with primary end point of hospital admission assessment. Treatment strategy for PCR positive COVID-19 subjects in the registry who are in Stage I of the disease process with ECL-19 drug compared to placebo in reducing hospital admissions

Eligibility criteria

Qualifiers

COVID-19 PCR positive

COVID-19 PCR negative

COVID-19 PCR pending

COVID-19 high risk score

Disqualifiers

Subjects unwilling to participate in the study before, during or after consent

Patients considered unreliable by the investigator concerning the requirements for follow-up visits.

Trial design

Treatments tested in this trial

  • Coromec Registry with ECL-19

Treatment groups

27,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Aventyn, Inc.

Lead sponsor

Intel Corporation

Collaborator

Abrazo Health Network

Collaborator

Karolinska Institutet

Collaborator

ASU College of Health Solutions

Collaborator